Double Medical(SZ:002901) Sou Hu Cai Jing·2025-12-29 12:31Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Dabo Medical (002901) as of December 29, 2025, showing a slight decline in stock price and notable changes in capital flow [1][2]. Group 2 - Dabo Medical reported a main revenue of 1.876 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 22.69% [2]. - The net profit attributable to shareholders for the same period was 425 million yuan, up 77.03% year-on-year, while the net profit after deducting non-recurring items was 346 million yuan, an increase of 63.99% [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 666 million yuan, reflecting a year-on-year growth of 17.82% [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, up 77.49% year-on-year, and the net profit after deducting non-recurring items was 123 million yuan, increasing by 38.44% [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan, while the gross profit margin is 71.23% [2]. - Dabo Medical specializes in the production, research, and sales of high-value medical consumables [2]. Group 3 - Over the last 90 days, one institution has given a buy rating for Dabo Medical [3]. - The capital flow data indicates a net outflow of 9.4984 million yuan from main funds, accounting for 12.08% of the total transaction amount, while retail investors saw a net inflow of 8.1568 million yuan, representing 10.37% of the total transaction amount [1].